Patients with CaV2.1 channelopathies face severe and often debilitating symptoms, such as seizures, migraines, tremors, and developmental delays. Although some symptoms overlap among these rare neurological conditions, patients often have different underlying mutations. In a recent study published in The FASEB Journal, researchers report the effects of two human CaV2.1 channelopathy mutations in a rat model, the findings of which could result in personalized therapies.
This article was originally published on MedicalXpress.com
